India and Uzbekistan have jointly introduced a pharmaceutical and nutraceutical trade corridor aimed at connecting Indian manufacturers with markets across the Commonwealth of Independent States (CIS) and the broader Eurasian region. According to reports, the combined opportunity in healthcare and dietary supplements across these markets is estimated at $7–10 billion.
Collaboration Behind the Initiative
The trade corridor has been developed through collaboration between the Ministry of Health of Uzbekistan, Nutrify Today and Pharma Eurasia.
The initiative aims to create a structured pathway for companies seeking to export medicines, nutraceuticals and healthcare products to CIS countries. By providing an organised framework, the corridor is expected to simplify market entry for businesses in the pharmaceutical and health supplement sectors.
Growing Demand in CIS Health Markets
Several CIS countries have witnessed rising demand for dietary supplements, vitamins, herbal formulations and preventive healthcare products. The increasing availability of these products through organised pharmacy networks has contributed to steady market growth.
The CIS dietary supplements market alone is estimated to exceed $5.8 billion annually. When combined with broader pharmaceutical and nutraceutical demand across Eurasian markets, the total opportunity is projected to reach between $7 billion and $10 billion.
How the Corridor Will Function
The corridor is expected to facilitate regulatory coordination, trade processes and distribution partnerships between participating regions. It will help companies manage approval procedures, documentation requirements and supply chain arrangements needed to operate in multiple markets.
Through this platform, Indian manufacturers may collaborate with regional distributors and firms across Eurasia. The framework could support partnerships, supply agreements and contract manufacturing arrangements, enabling smoother market expansion.
Uzbekistan’s Push to Develop Pharma Sector
Uzbekistan has introduced several policy measures to strengthen its domestic pharmaceutical industry. These include the development of pharmaceutical parks and reforms aimed at simplifying regulatory approvals and manufacturing processes.
The government has also launched investment promotion programmes designed to attract international pharmaceutical companies and contract development partners.
Strategic Location for Regional Trade
Uzbekistan’s geographic position between India, Russia and Central Asia places it along key regional trade routes. This location allows companies operating in the country to access multiple CIS markets using existing logistics and transport networks.
The country is also developing industrial clusters and infrastructure projects to support pharmaceutical manufacturing, distribution and exports.
Upcoming Industry Engagement in Tashkent
Commercial discussions related to the corridor are expected to take place during Pharma Eurasia 2026, scheduled to be held in Tashkent from May 20 to May 22.
The event is expected to bring together manufacturers, ingredient suppliers, contract manufacturers, distributors and regulatory authorities from across the Eurasian region.
Summary:
India and Uzbekistan have launched a pharmaceutical and nutraceutical trade corridor aimed at connecting Indian companies with CIS and Eurasian markets. The initiative, supported by industry and government stakeholders, is designed to streamline regulatory processes and facilitate partnerships, targeting a healthcare and supplements market estimated at $7–10 billion.
This article is intended solely for educational and informational purposes. The securities or companies mentioned are provided as examples and should not be considered as recommendations. Nothing contained herein constitutes personal financial advice or investment recommendations. Readers are advised to conduct their own research and consult a qualified financial advisor before making any investment decisions.
Investments in securities markets are subject to market risks. Please read all related documents carefully before investing.
